Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

Inclusion Criteria:

- Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma
with or without metastases

- Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2

- Anticipated life expectancy ≥ 12 weeks

- Radiographically measurable disease acc. to RECIST 1.1

- Use of adequate contraception (as described in protocol)

- Ability to provide written informed consent and comply with study requirements

Exclusion Criteria:

- Received other cancer treatment or investigational drug within 4 weeks prior to
screening

- Women who are pregnant or breastfeeding

- Had major surgery within 4 weeks of first dose of study drug

- Inadequate liver, renal or bone marrow function within 2 weeks of first dose

- Serious concurrent illness, altered medical status or any uncontrolled medical
condition

- Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening

- Known active HIV, HBV or HCV infection

- Inability to swallow tablets

- History or presence of any medical condition or disease which, in the opinion of the
investigator, may place the subject at unacceptable risk for study participation